Third degree AV block primary prevention: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Third degree AV block}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== ...")
 
 
(9 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Third degree AV block}}
{{Third degree AV block}}
{{CMG}}; {{AE}} {{Sara.Zand}}
==Overview==
Effective measurement  for primary prevention of [[atrioventricular block]] due to [[dogoxine]] toxicity in  [[patients]] with [[renal insufficiency]] is avoidance of [[dehydration]], [[electrolytes imbalance]] and careful monitoring about [[heart block]].


Please help WikiDoc by adding content here. It's easy!  Click [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
==Primary prevention==
*Effective measurement for primary prevention of [[atrioventricular block]] due to [[dogoxin toxicity]] in [[patients]] with [[renal insufficiency]] is avoidance of [[dehydration]], and [[electrolytes imbalance]] and careful monitoring about [[heart block]].<ref name="pmid6632915">{{cite journal |vauthors=Adamantidis MM, Duriez PR, Vincent AC, Dupuis BA |title=Digoxin-induced toxicity and experimental atrioventricular block in dogs. Relation between ventricular arrhythmias and oscillatory afterpotentials |journal=J Pharmacol |volume=14 |issue=3 |pages=333–49 |date=1983 |pmid=6632915 |doi= |url=}}</ref>
* In [[patients]] with [[renal]] insufficiency, [[potassium]], [[electrolyte disturbances]], and [[dehydration]] are predisposed to develop [[digoxin toxicity]].
* Careful monitoring of [[electrolytes]], [[drug]] levels, and [[renal function]] is essential in [[patients]] on [[chronic]] [[digoxin ]] therapy.
* [[Patients]] on multiple [[AV nodal blocker]] agents (e.g., [[beta-blockers]] and [[calcium channel blockers]]) are at an increased risk for the development of [[atrioventricular (AV) block ]].
* These [[patients]] should be carefully monitored for [[heart blocks]].
*[[Primary prevention]]  of [[congenital]] [[complete heart block]] or [[second-degree AV block]] for [[women ]] with [[SLE]] include taking [[hydroxychloroquine]] prior to [[conception]].<ref name="pmid30137589">{{cite journal| author=Clowse MEB, Eudy AM, Kiernan E, Williams MR, Bermas B, Chakravarty E et al.| title=The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. | journal=Rheumatology (Oxford) | year= 2018 | volume= 57 | issue= suppl_5 | pages= v9-v17 | pmid=30137589 | doi=10.1093/rheumatology/key141 | pmc=6099126 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30137589  }}</ref>
 
<br />


==References==
==References==

Latest revision as of 08:56, 24 July 2021

Third degree AV block Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Third degree AV block from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Third degree AV block primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Third degree AV block primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Third degree AV block primary prevention

CDC on Third degree AV block primary prevention

Third degree AV block primary prevention in the news

Blogs on Third degree AV block primary prevention

Directions to Hospitals Treating Third degree AV block

Risk calculators and risk factors for Third degree AV block primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Zand, M.D.[2]

Overview

Effective measurement for primary prevention of atrioventricular block due to dogoxine toxicity in patients with renal insufficiency is avoidance of dehydration, electrolytes imbalance and careful monitoring about heart block.

Primary prevention


References

  1. Adamantidis MM, Duriez PR, Vincent AC, Dupuis BA (1983). "Digoxin-induced toxicity and experimental atrioventricular block in dogs. Relation between ventricular arrhythmias and oscillatory afterpotentials". J Pharmacol. 14 (3): 333–49. PMID 6632915.
  2. Clowse MEB, Eudy AM, Kiernan E, Williams MR, Bermas B, Chakravarty E; et al. (2018). "The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices". Rheumatology (Oxford). 57 (suppl_5): v9–v17. doi:10.1093/rheumatology/key141. PMC 6099126. PMID 30137589.


Template:WikiDoc Sources